TGTX beat EPS expectations by 77.10%
Mar 03, 2025, 11:31 PM
0.00%
What does TGTX do
TG Therapeutics, based in Morrisville, North Carolina, develops treatments for B-cell malignancies and autoimmune diseases, with key candidates including Ublituximab, TG-1701, and TG-1801. The company employs 284 people and explores partnership opportunities for additional products.
TG Therapeutics (TGTX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, TG Therapeutics's actual EPS was $0.15, beating the estimate of $0.08 per share, resulting in a 77.10% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
